Regression to the mean inflates accuracy in machine learning prediction of symptom change – Nature Mental Health

Competing interests

J.R. has received continuing medical education (CME) honoraria from Inspira Networks and Evidenze Health for machine learning courses promoted by Adamed and Viatris, outside the submitted work. E.V. has received grants and served as a consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Adium, Alcediag, Angelini, Biogen, Beckley Psytech, Biohaven, Boehringer Ingelheim, Casen-Recordati, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, GlaxoSmithKline, HMNC, Intra-Cellular Therapies, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Mitsubishi Tanabe Pharma, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva and Viatris, outside the submitted work. The other authors declare no competing interests.